Search
Ethylmercurithiosalicylic acid
go.drugbank.com/drugs/DB02731ExperimentalEthylmercurithiosalicylic acid is a topical antiseptic used on skin and mucous membranes. It is also used as a preservative in pharmaceuticals.
Meglutol
go.drugbank.com/drugs/DB04377Experimentalis the rate limiting enzyme in the biosynthesis of cholesterol. … An antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids.
AP5280
go.drugbank.com/drugs/DB05112ExperimentalAP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.
Arundic acid
go.drugbank.com/drugs/DB05343InvestigationalArundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Fluindione
go.drugbank.com/drugs/DB13136ApprovedWithdrawnFluindione is under investigation for the treatment of Venous Thrombosis, Pulmonary Embolism, Permanent Atrial Fibrillation, and Anticoagulating Treatment on a Duration at Least 12-month-old Superior.
Padoprazan
go.drugbank.com/drugs/DB21689ExperimentalThe usage of the INN stem '-prazan' in the name indicates that Padoprazan is a proton pump inhibitor, not dependent on acid activation. Padoprazan has a monoisotopic molecular weight of 405.12 Da.
BI-K0376
go.drugbank.com/drugs/DB05858ExperimentalBI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Oftasceine
go.drugbank.com/drugs/DB11184ApprovedIt is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.
Aspartyl-alanyl-diketopiperazine
go.drugbank.com/drugs/DB14940InvestigationalAspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).
EU204
go.drugbank.com/drugs/DB17438InvestigationalEU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.